Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial
Por:
Català-Moll, F, Blázquez-Bondia, C, Farré-Badia, J, Torres, F, Manzardo, C, Bonfill, E, Curran, A, Domingo, P, Podzamczer, D, Force, L, Falcó, V, Parera, M, Casadellà, M, Miró, JM, Noguera-Julian, M and Paredes, R
Publicada:
4 mar 2026
Resumen:
Late presentation of HIV-1 infection is linked to gut dysbiosis, impaired immune reconstitution, excess inflammation, immune activation, and increased morbidity and mortality. It is unclear if antiretroviral therapy initiation can reverse HIV-associated gut dysbiosis at all, or if specific antiretroviral regimens are more effective in restoring the gut microbiota than others. This has important implications for the long-term health of individuals with HIV. In this multicenter, open-label, randomized clinical trial (NCT02337322), 88 antiretroviral-na & iuml;ve individuals with advanced HIV-1 infection (median CD4+ T cells of 34 cells/mm3) were randomized (1:1) to initiate lamivudine/abacavir plus either dolutegravir or ritonavir-boosted darunavir, and were followed for 2 years. Both groups had similar HIV-1 suppression rates and recovery of CD4+ T cells. However, treatment with dolutegravir led to increased gut microbial richness and diversity and enrichment of specific microbial taxa and metabolic pathways. These changes were associated with reduced inflammation and lower immune activation, outcomes that did not occur with darunavir/ritonavir. After two years, participants on dolutegravir-based therapy had gut microbiota profiles more closely resembling those of people without HIV, compared to individuals taking darunavir/ritonavir. In summary, dolutegravir-based therapy restores the gut microbiota more effectively than darunavir/ritonavir in patients who present late with HIV.
Filiaciones:
:
IrsiCaixa, Badalona, Barcelona, Spain
Carlos III Hlth Inst, Infect Dis Networking Biomed Res Ctr, Ctr Invest Biomed Red Enfermedades Infecciosas, Madrid, Spain
Blázquez-Bondia, C:
IrsiCaixa, Badalona, Barcelona, Spain
Univ Autonoma Barcelona, Bellaterra, Catalonia, Spain
Farré-Badia, J:
IrsiCaixa, Badalona, Barcelona, Spain
Torres, F:
Univ Barcelona, Hosp Clin IDIBAPS, Barcelona, Catalonia, Spain
Univ Autonoma Barcelona, Med Sch, Biostat Unit, Bellaterra, Catalonia, Spain
Manzardo, C:
Univ Barcelona, Hosp Clin IDIBAPS, Barcelona, Catalonia, Spain
Bonfill, E:
Univ Barcelona, Hosp Clin IDIBAPS, Barcelona, Catalonia, Spain
Curran, A:
Univ Autonoma Barcelona, Bellaterra, Catalonia, Spain
Hosp Univ Vall dHebron VHIR, Barcelona, Catalonia, Spain
Domingo, P:
Hosp Univ Santa Creu & St Pau, Barcelona, Catalonia, Spain
Podzamczer, D:
Hosp Univ Bellvitge, Lhospitalet De Llobregat, Catalonia, Spain
Force, L:
Hosp Univ Mataro, Barcelona, Catalonia, Spain
Falcó, V:
Univ Autonoma Barcelona, Bellaterra, Catalonia, Spain
Hosp Univ Vall dHebron VHIR, Barcelona, Catalonia, Spain
:
IrsiCaixa, Badalona, Barcelona, Spain
:
IrsiCaixa, Badalona, Barcelona, Spain
Univ Autonoma Barcelona, Bellaterra, Catalonia, Spain
Miró, JM:
Carlos III Hlth Inst, Infect Dis Networking Biomed Res Ctr, Ctr Invest Biomed Red Enfermedades Infecciosas, Madrid, Spain
Univ Barcelona, Hosp Clin IDIBAPS, Barcelona, Catalonia, Spain
Reial Acad Med Catalunya, Barcelona, Spain
Noguera-Julian, M:
IrsiCaixa, Badalona, Barcelona, Spain
:
IrsiCaixa, Badalona, Barcelona, Spain
Carlos III Hlth Inst, Infect Dis Networking Biomed Res Ctr, Ctr Invest Biomed Red Enfermedades Infecciosas, Madrid, Spain
Univ Politecn Catalunya BarcelonaTech, Terrassa, Catalonia, Spain
Hosp Badalona Germans Trias & Pujol, Dept Infect Dis, Badalona, Catalonia, Spain
Case Western Reserve Univ, Sch Med, Ctr Global Hlth & Dis, Dept Pathol, Cleveland, OH 44106 USA
Hosp Badalona Germans Trias & Pujol, Fundacio Lluita Infecc, Badalona, Spain
Green Submitted, gold
|